molecules of the month


CNS pen. GPR6 GPCR inverse agonist

oral QD Ph. II candidate for ParkinsonÕs

from 360k cmpd cell-based HTS + opt.

J. Pharmacol. Exp. Ther., Apr. 1, 2021

Cerevance / Takeda California, San Diego, US

Structure of CVN424
1 min read

The Cerevance/Takeda GPR6 inverse agonist (CVN424) is an oral, once-daily clinical candidate in Ph. II for Parkinson’s disease after completing a Ph. I in healthy volunteers. Its >40 µM starting point was discovered through a 360k compound cell-based HTS targeting human GPR6 (an orphan GPCR). The molecule CVN424 is interesting because it is brain penetrant and orally available even with five rings and numerous polar atoms and metabolic soft spots. In vivo, CVN424 increases locomotor activity, reverses haloperidol induced catalepsy and restores mobility in a bilateral 6-OHDA lesion model of Parkinson’s disease. With its non-dopaminergic mechanism, CVN424 is a potential drug for treating the motor symptoms of PD with a reduced risk of adverse effects such as L-DOPA induced dyskinesias.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: